Biotech | February 23, 2022
Merck completes acquisition of biopharma CDMO Exelead
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
